# EDGAR Filing Document

**Accession Number:** 0001477449
**File Stem:** 0001477449-26-000028
**Filing Date:** 2026-4
**Character Count:** 137283
**Document Hash:** eb839637af6aef2ff135c4e2e4c41dbb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477449-26-000028.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001477449-26-000028

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 76

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Teladoc Health, Inc.
- **CENTRAL INDEX KEY:** 0001477449
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043705970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37477
- **FILM NUMBER:** 26920723

**BUSINESS ADDRESS:**
- **STREET 1:** 155 E 44TH STREET
- **STREET 2:** SUITE 1700
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 2036352002

**MAIL ADDRESS:**
- **STREET 1:** 155 E 44TH STREET
- **STREET 2:** SUITE 1700
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Teladoc, Inc.
- **DATE OF NAME CHANGE:** 20091123

?xml version='1.0' encoding='ASCII'? tdoc-20260331

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**_________________________________________________________________________________________________________**

**Form 10-Q**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**or**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from** 

**to** 

**Commission File Number: 001-37477**

**______________________________________**

**TELADOC HEALTH, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **04-3705970** |
| (State of incorporation) | (I.R.S. Employer Identification No.) |
| **155 E 44th Street, Suite 1700** | |
| **New York, New York** | **10017** |
| (Address of principal executive office) | (Zip code) |

---

**(203) 635-2002** 

(Registrant's telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | TDOC | New York Stock Exchange |

---

**______________________________________**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | □ | Non-accelerated filer | □ | Smaller reporting company | □ |
| Emerging growth company | □ | | | | | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

As of April 23, 2026, the Registrant had 180,513,087 shares of Common Stock outstanding.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**TELADOC HEALTH, INC.**

**QUARTERLY REPORT ON FORM 10-Q**

**For the period ended March 31, 2026**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page<br>Number** |
| <u>[PART I](#i4494206693f04f999e24db88e0075fbb_10)</u> | <u>[Financial Information](#i4494206693f04f999e24db88e0075fbb_10)</u> | [2](#i4494206693f04f999e24db88e0075fbb_10) |
| <u>[Item 1.](#i4494206693f04f999e24db88e0075fbb_13)</u> | <u>[Financial Statements](#i4494206693f04f999e24db88e0075fbb_13)</u> | [2](#i4494206693f04f999e24db88e0075fbb_13) |
|  | <u>[Condensed Consolidated Balance Sheets as of](#i4494206693f04f999e24db88e0075fbb_16)[March 31](#i4494206693f04f999e24db88e0075fbb_16)[, 202](#i4494206693f04f999e24db88e0075fbb_16)[6](#i4494206693f04f999e24db88e0075fbb_16)[(unaudited) and December 31, 202](#i4494206693f04f999e24db88e0075fbb_16)[5](#i4494206693f04f999e24db88e0075fbb_16)</u> | [2](#i4494206693f04f999e24db88e0075fbb_16) |
|  | <u>[Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three](#i4494206693f04f999e24db88e0075fbb_19)[months ended](#i4494206693f04f999e24db88e0075fbb_19)[March](#i4494206693f04f999e24db88e0075fbb_19)[3](#i4494206693f04f999e24db88e0075fbb_19)[1](#i4494206693f04f999e24db88e0075fbb_19)[, 202](#i4494206693f04f999e24db88e0075fbb_19)[6](#i4494206693f04f999e24db88e0075fbb_19)[and 202](#i4494206693f04f999e24db88e0075fbb_19)[5](#i4494206693f04f999e24db88e0075fbb_19)</u> | [3](#i4494206693f04f999e24db88e0075fbb_19) |
|  | <u>[Condensed Consolidated Statements of Stockholders' Equity (unaudited) for the three](#i4494206693f04f999e24db88e0075fbb_22)[months ended](#i4494206693f04f999e24db88e0075fbb_22)[March](#i4494206693f04f999e24db88e0075fbb_22)[3](#i4494206693f04f999e24db88e0075fbb_22)[1](#i4494206693f04f999e24db88e0075fbb_22)[, 202](#i4494206693f04f999e24db88e0075fbb_22)[6](#i4494206693f04f999e24db88e0075fbb_22)[and 20](#i4494206693f04f999e24db88e0075fbb_22)[2](#i4494206693f04f999e24db88e0075fbb_22)[5](#i4494206693f04f999e24db88e0075fbb_22)</u> | [4](#i4494206693f04f999e24db88e0075fbb_22) |
|  | <u>[Condensed Consolidated Statements of Cash Flows (unaudited) for the](#i4494206693f04f999e24db88e0075fbb_25)[three](#i4494206693f04f999e24db88e0075fbb_25)[months ended](#i4494206693f04f999e24db88e0075fbb_25)[March](#i4494206693f04f999e24db88e0075fbb_25)[3](#i4494206693f04f999e24db88e0075fbb_25)[1](#i4494206693f04f999e24db88e0075fbb_25)[, 202](#i4494206693f04f999e24db88e0075fbb_25)[6](#i4494206693f04f999e24db88e0075fbb_25)[and 202](#i4494206693f04f999e24db88e0075fbb_25)[5](#i4494206693f04f999e24db88e0075fbb_25)</u> | [5](#i4494206693f04f999e24db88e0075fbb_25) |
|  | <u>[Notes to Unaudited Condensed Consolidated Financial Statements](#i4494206693f04f999e24db88e0075fbb_28)</u> | [6](#i4494206693f04f999e24db88e0075fbb_28) |
| <u>[Item 2.](#i4494206693f04f999e24db88e0075fbb_88)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i4494206693f04f999e24db88e0075fbb_88)</u> | [22](#i4494206693f04f999e24db88e0075fbb_88) |
| <u>[Item 3.](#i4494206693f04f999e24db88e0075fbb_115)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i4494206693f04f999e24db88e0075fbb_115)</u> | [32](#i4494206693f04f999e24db88e0075fbb_115) |
| <u>[Item 4.](#i4494206693f04f999e24db88e0075fbb_118)</u> | <u>[Controls and Procedures](#i4494206693f04f999e24db88e0075fbb_118)</u> | [33](#i4494206693f04f999e24db88e0075fbb_118) |
| <u>[PART II](#i4494206693f04f999e24db88e0075fbb_121)</u> | <u>[Other Information](#i4494206693f04f999e24db88e0075fbb_121)</u> | [34](#i4494206693f04f999e24db88e0075fbb_121) |
| <u>[Item 1.](#i4494206693f04f999e24db88e0075fbb_124)</u> | <u>[Legal Proceedings](#i4494206693f04f999e24db88e0075fbb_124)</u> | [34](#i4494206693f04f999e24db88e0075fbb_124) |
| <u>[Item 1A.](#i4494206693f04f999e24db88e0075fbb_127)</u> | <u>[Risk Factors](#i4494206693f04f999e24db88e0075fbb_127)</u> | [34](#i4494206693f04f999e24db88e0075fbb_127) |
| <u>[Item 5.](#i4494206693f04f999e24db88e0075fbb_130)</u> | <u>[Other Information](#i4494206693f04f999e24db88e0075fbb_130)</u> | [34](#i4494206693f04f999e24db88e0075fbb_130) |
| <u>[Item 6.](#i4494206693f04f999e24db88e0075fbb_136)</u> | <u>[Exhibits](#i4494206693f04f999e24db88e0075fbb_136)</u> | [35](#i4494206693f04f999e24db88e0075fbb_136) |
| <u>[Exhibit Index](#i4494206693f04f999e24db88e0075fbb_139)</u> | <u>[Exhibit Index](#i4494206693f04f999e24db88e0075fbb_139)</u> | [35](#i4494206693f04f999e24db88e0075fbb_139) |
| <u>[Signatures](#i4494206693f04f999e24db88e0075fbb_142)</u> | <u>[Signatures](#i4494206693f04f999e24db88e0075fbb_142)</u> | [36](#i4494206693f04f999e24db88e0075fbb_142) |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**PART I**

**FINANCIAL INFORMATION**

**ITEM 1. *Financial Statements***

**TELADOC HEALTH, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands, except share data, unaudited)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **ASSETS** | | |
| **Current assets:** | | |
| Cash and cash equivalents | $750738 | $781084 |
| Accounts receivable, net of allowance for doubtful accounts of $3,016 and $4,033 at March 31, 2026 and December 31, 2025, respectively | 213627 | 192826 |
| Inventories | 31557 | 38203 |
| Prepaid expenses and other current assets | 136417 | 107016 |
| **Total current assets** | 1132339 | 1119129 |
| Property and equipment, net | 26278 | 26972 |
| Goodwill | 283190 | 283190 |
| Intangible assets, net | 1235185 | 1297087 |
| Operating lease—right-of-use assets | 24233 | 26119 |
| Other assets | 106036 | 105803 |
| **Total assets** | $2807261 | $2858300 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable | $45196 | $47967 |
| Accrued expenses and other current liabilities | 233292 | 198208 |
| Accrued compensation | 60668 | 96258 |
| Deferred revenue, current | 65714 | 62305 |
| **Total current liabilities** | 404870 | 404738 |
| Operating lease liabilities, net of current portion | 31738 | 34204 |
| Deferred revenue, net of current portion | 10365 | 9139 |
| Deferred taxes, net | 27610 | 28945 |
| Convertible senior notes, net | 995811 | 994925 |
| Other liabilities | 551 | 643 |
| **Total liabilities** | 1470945 | 1472594 |
| **Commitments and contingencies (Note 14)** |  |  |
| **Stockholders' equity:** |  |  |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 180,431,102 shares and 178,315,400 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 180 | 178 |
| Additional paid-in capital | 17865617 | 17850478 |
| Accumulated deficit | (16494059) | (16430222) |
| Accumulated other comprehensive loss | (35422) | (34728) |
| **Total stockholders' equity** | 1336316 | 1385706 |
| **Total liabilities and stockholders' equity** | $2807261 | $2858300 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**TELADOC HEALTH, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS** 

**(In thousands, except share and per share data, unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Revenue** | $613845 | $629369 |
| **Costs and expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 197526 | 196829 |
| &nbsp;&nbsp;&nbsp;Advertising and marketing | 151527 | 168185 |
| &nbsp;&nbsp;&nbsp;Sales | 51276 | 48693 |
| &nbsp;&nbsp;&nbsp;Technology and development | 67865 | 69958 |
| &nbsp;&nbsp;&nbsp;General and administrative | 102093 | 112774 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment |  | 59138 |
| &nbsp;&nbsp;&nbsp;Acquisition, integration, and transformation costs | 1064 | 2188 |
| &nbsp;&nbsp;&nbsp;Restructuring costs | 11975 | 4347 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 89826 | 84304 |
| &nbsp;&nbsp;&nbsp;Depreciation of property and equipment | 2461 | 3564 |
| **Total costs and expenses** | 675613 | 749980 |
| **Loss from operations** | (61768) | (120611) |
| Interest income | (6490) | (12674) |
| Interest expense | 5368 | 5765 |
| Other expense (income), net | 196 | (2435) |
| **Loss before provision for income taxes** | (60842) | (111267) |
| Provision for income taxes | 2995 | (18255) |
| **Net loss** | (63837) | (93012) |
| Other comprehensive (loss) income, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;Currency translation adjustment | (694) | 1143 |
| **Comprehensive loss** | $(64531) | $(91869) |
| Net loss per share, basic and diluted | $(0.36) | $(0.53) |
| Weighted-average shares used to compute basic and diluted net loss per share | 179122268 | 174154128 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**TELADOC HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(In thousands, except share data, unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Total<br>Stockholders'<br>Equity** |
| Balances as of December 31, 2025 | 178315400 | $178 | $17850478 | $(16430222) | $(34728) | $1385706 |
| &nbsp;&nbsp;Issuance of common stock upon vesting of restricted stock units | 2115702 | 2 | (2) |  |  |  |
| &nbsp;&nbsp;Stock-based compensation |  |  | 15141 |  |  | 15141 |
| &nbsp;&nbsp;Other comprehensive loss, net of tax |  |  |  |  | (694) | (694) |
| &nbsp;&nbsp;Net loss |  |  |  | (63837) |  | (63837) |
| Balances as of March 31, 2026 | 180431102 | $180 | $17865617 | $(16494059) | $(35422) | $1336316 |
| Balances as of December 31, 2024 | 173405016 | $173 | $17759194 | $(16229900) | $(38388) | $1491079 |
| &nbsp;&nbsp;Exercise of stock options | 10607 |  | 80 |  |  | 80 |
| &nbsp;&nbsp;Issuance of common stock upon vesting of restricted stock units | 1924702 | 2 | (2) |  |  |  |
| &nbsp;&nbsp;Stock-based compensation |  |  | 27740 |  |  | 27740 |
| &nbsp;&nbsp;Other comprehensive income, net of tax |  |  |  |  | 1143 | 1143 |
| &nbsp;&nbsp;Net loss |  |  |  | (93012) |  | (93012) |
| Balances as of March 31, 2025 | 175340325 | $175 | $17787012 | $(16322912) | $(37245) | $1427030 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**TELADOC HEALTH, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands, unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(63837) | $(93012) |
| Adjustments to reconcile net loss to net cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment |  | 59138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 89826 | 84304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 14611 | 25163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation of property and equipment | 2461 | 3564 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use assets | 1898 | 2305 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for allowances for doubtful accounts | (79) | 59 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (1060) | (26865) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | 1329 | 1753 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (20996) | (15270) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (29446) | (23786) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 6315 | 1515 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 336 | 412 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (2108) | 17356 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 39114 | 12568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | (31529) | (21463) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 5060 | (5542) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (2297) | (2482) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | (82) | (3798) |
| Net cash provided by operating activities | 9516 | 15919 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (1660) | (2726) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized software development costs | (34162) | (28859) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions accounted for as business combinations, net of cash acquired |  | (64608) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments for investments | (700) | (27075) |
| Net cash used in investing activities | (36522) | (123268) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of stock options |  | 80 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from employee stock purchase plan | 399 | 689 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (2848) |  |
| Net cash (used in) provided by financing activities | (2449) | 769 |
| Net decrease in cash and cash equivalents | (29455) | (106580) |
| Effect of foreign currency exchange rate changes | (891) | 1585 |
| Cash and cash equivalents at beginning of the period | 781084 | 1298327 |
| Cash and cash equivalents at end of the period | $750738 | $1193332 |
| Cash (received) paid for income taxes, net | $(42) | $328 |
| **<u>Supplemental disclosure of non-cash investing activities</u>** |  |  |
| Accruals related to Intangible assets, net and Property and equipment, net | $4823 | $4271 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**TELADOC HEALTH, INC.** 

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1. Organization and Description of Business**

Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as "Teladoc Health" or the "Company." The Company's principal executive office is located in New York, New York. Teladoc Health is the global leader in virtual care. The Company's mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience.

**Note 2. Basis of Presentation and Principles of Consolidation**

The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2026 and 2025, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the Condensed Consolidated Results of Operations, financial position and cash flows of Teladoc Health for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles ("GAAP") in the United States ("U.S.") have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). The information in this report should be read in conjunction with the Company's Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2025 (the "2025 Form 10-K"), which includes a complete set of footnote disclosures, including the Company's significant accounting policies.

These consolidated financial statements include the results of Teladoc Health, as well as three professional associations and 10 professional corporations that comprise the "THMG Association" and five professional corporations that comprise the "Uplift Association."

Teladoc Health Medical Group, P.A. ("THMG") is party to a services agreement by and among it and the other professional associations and professional corporations in the THMG Association pursuant to which each professional association and professional corporation provides services to THMG. Each professional association and professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.

Uplift Behavioral Health, P.C. ("Uplift PC") is party to a services agreement by and among it and the other professional corporations in the Uplift Association pursuant to which each professional corporation provides services to Uplift PC. Each professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.

The Company holds a variable interest in the THMG Association and the Uplift Association, which each contract with physicians and other health professionals in order to provide services to Teladoc Health. The THMG Association and the Uplift Association are each considered a variable interest entity ("VIE") since each does not have sufficient equity to finance their respective activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control the activities that most significantly impact the THMG Association and the Uplift Association economic performance and funds and absorbs all losses of the VIE and appropriately consolidates the THMG Association and the Uplift Association.

Total revenue and net income for the VIEs were $104.1 million and $0.1 million and $80.2 million and $0.0 million for the three months ended March 31, 2026 and 2025, respectively. Total assets for the VIEs, all of which were current, were $41.1 million and $36.3 million at March 31, 2026 and December 31, 2025, respectively, and total liabilities, all of which were current, were $87.3 million and $82.6 million at March 31, 2026 and December 31, 2025,

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

respectively. Total stockholders' deficit for the VIEs was $46.2 million and $46.3 million at March 31, 2026 and December 31, 2025, respectively.

All intercompany transactions and balances have been eliminated.

***Use of Estimates***

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.

Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements.

Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the capitalization and amortization of software development costs, allowances for sales, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies (including earnouts), litigation and related legal accruals, the accounting for stock-based compensation awards, the probability assessment of satisfying vesting conditions for certain investments, and other items as described in Note 2. "Basis of Presentation and Principles of Consolidation" in the Summary of Significant Accounting Policies in the 2025 Form 10-K and as may be updated in this Quarterly Report in Note 2. "Basis of Presentation and Principles of Consolidation."

***Fair Value Measurements***

The carrying value of the Company's cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.

A financial instrument's classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2—Include other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs that are supported by little or no market activity.

The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets and quoted prices directly in active markets.

***Reclassifications***

Certain prior year amounts have been reclassified to conform to the current year presentation.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

***Recently Adopted Accounting Standards***

In July 2025, the FASB issued Accounting Standards Update ("ASU") 2025-05, "Measurement of Credit Losses for Accounts Receivable and Contract Assets." This new standard provides a practical expedient that all entities can use when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, "Revenue from Contracts with Customers." The practical expedient allows companies to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset when measuring credit losses. ASU 2025-05 was effective for annual periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods, with early adoption permitted. The adoption of this new ASU did not have an effect on the Company's financial statements.

***Recently Issued Accounting Standards***

In November 2024, the FASB issued ASU 2024-03, "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." ASU 2024-03 requires a public business entity ("PBE") to disclose information in the notes to financial statements about purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depletion for each income statement line item that contains those expenses. Entities would also have to disclose other specific expenses, gains, or losses that are already required to be disclosed under GAAP in this same disclosure, a qualitative description of the amounts remaining that are not separately disaggregated quantitatively, and the total amount of selling expenses, as well as the PBE's definition of selling expenses. In January 2025, the FASB Issued ASU No. 2025-01, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)," which clarified that ASU 2024-03 is effective for public business entities for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. Implementation of ASU 2024-03 may be applied prospectively or retrospectively. The Company is currently evaluating these new disclosure requirements and the impact of adoption.

In May 2025, the FASB issued ASU 2025-03, "Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity," which clarifies current guidance for determining the accounting acquirer for a transaction effected primarily by exchanging equity interests in which the legal acquiree is a variable interest entity that meets the definition of a business. ASU 2025-03 is effective for annual reporting periods beginning after December 15, 2026, including interim reporting periods within those annual reporting periods, with early adoption permitted. The Company does not currently expect that the adoption of ASU 2025-03 will impact its existing financial statements but could impact the determination of the accounting acquirer in future business combinations that involve variable interest entities.

In May 2025, the FASB issued ASU 2025-04, "Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer." This new standard clarifies the accounting for share-based consideration payable to a customer under Topics 718 and 606. Key changes include expanding the "performance condition" definition, requiring an estimate of forfeitures, and clarifying the measurement guidance. ASU 2025-04 is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company expects that the adoption of ASU 2025-04 will not have a material effect on its financial statements.

In September 2025, the FASB issued ASU 2025-06, "Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software." This new standard provides updated guidance on the capitalization and disclosure of internal-use software costs, including cloud computing arrangements and enhancements to qualitative and quantitative disclosures. The amendments aim to clarify when capitalization should begin and end, and require enhanced disclosures to provide greater transparency about software development spending and amortization patterns. ASU 2025-06 is effective for annual periods beginning after December 15, 2027 and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact of adopting this new guidance on its financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, "Interim Reporting (Topic 270): Narrow-Scope Improvements," which intends to improve the navigability of the guidance in ASC 270 and clarify the applicability of the interim reporting guidance, the types of interim reporting, and the form and content of interim financial statements in accordance with GAAP. ASU 2025-11 is effective for annual periods beginning after December 15, 2027, and interim

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

periods within those annual periods, with early adoption permitted. The Company expects that the adoption of ASU 2025-11 will not have a material impact on its financial statements and related disclosures.

**Note 3. Revenue, Deferred Revenue, and Deferred Device and Contract Costs**

The Company generates access fees from customers, which primarily consist of employers, health plans, hospitals and health systems, insurance and financial services companies (collectively "Clients"), as well as individual paying users, accessing the THMG Association professional provider network, the Uplift Association professional provider network, and the Company's therapy and other wellness platforms, hosted virtual care platform, and chronic care management platforms. Visit fee revenue is generated for general medical, expert medical service, virtual therapy, and other specialty visits, and is reported as a component of other revenue. Revenue associated with virtual care device equipment sales included with the Company's hosted virtual care platform is also reported in other revenue.

The following table presents the Company's revenues disaggregated by revenue source and geography (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Revenue by Type** |  |  |
| Access Fees | $484655 | $525736 |
| Other | 129190 | 103633 |
| Total Revenue | $613845 | $629369 |
| **Revenue by Geography** |  |  |
| U.S. | $491505 | $524970 |
| International | 122340 | 104399 |
| Total Revenue | $613845 | $629369 |

---

***Deferred Revenue***

Deferred revenue represents billed, but unrecognized revenue, and is comprised of fees received in advance of the delivery or completion of the services and amounts received in instances when revenue recognition criteria have not been met. The Company records deferred revenue when cash payments are received in advance of the Company's performance obligation to provide services. Deferred revenue is derived from 1) upfront payments for a device, which is amortized ratably over the expected member enrollment period; 2) upfront payments for certain services where payment is required for future periods before the service is delivered to the member, which is recognized when the services are provided; and 3) upfront payments from third-party financing companies with whom the Company works to provide certain Clients with a rental option, which is recognized over the rental period. Deferred revenue that will be recognized during the next twelve-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue.

The following table summarizes deferred revenue activities for the periods presented (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Beginning balance | $71444 | $89082 |
| &nbsp;&nbsp;&nbsp;Balances assumed as part of business acquisitions |  | 27 |
| &nbsp;&nbsp; Cash collected | 43515 | 55903 |
| &nbsp;&nbsp; Revenue recognized | (38880) | (60833) |
| Ending balance | $76079 | $84179 |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

The Company expects to recognize revenue of $61.4 million throughout the remainder of 2026, $10.8 million of revenue in the year ending December 31, 2027, and the remaining balance thereafter related to future performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2026.

***Deferred Device and Contract Costs***

Deferred device and contract costs are classified as a component of prepaid expenses and other current assets or other assets, depending on term, and consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Deferred device and contract costs, current | $37377 | $31820 |
| Deferred device and contract costs, non-current | 15563 | 14129 |
| Total deferred device and contract costs | $52940 | $45949 |

---

Deferred device and contract costs were as follows (in thousands):

---

| | |
|:---|:---|
| | **Deferred Device and Contract Costs** |
| Beginning balance as of December 31, 2025 | $45949 |
| &nbsp;&nbsp;&nbsp;Additions | 19013 |
| &nbsp;&nbsp;&nbsp;Cost of revenue recognized | (12022) |
| Ending balance as of March 31, 2026 | $52940 |

---

**Note 4. Inventories**

Inventories consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Raw materials and purchased parts | $11276 | $13783 |
| Work in process | 1100 | 502 |
| Finished goods | 19181 | 23918 |
| Total inventories | $31557 | $38203 |

---

**Note 5. Prepaid Expenses and Other Current Assets**

Prepaid expenses and other current assets consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Prepaid expenses | $88195 | $64291 |
| Deferred device and contract costs, current | 37377 | 31820 |
| Other receivables | 8911 | 8834 |
| Other current assets | 1934 | 2071 |
| Total prepaid expenses and other current assets | $136417 | $107016 |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Note 6. Acquisitions**

**<u>Business Combinations</u>**

On February 28, 2025, Teladoc Health acquired full ownership of Catapult Health, LLC ("Catapult Health"). Including the final closing adjustments, the Company paid $65.3 million, which is net of $0.1 million of cash acquired, of which $64.6 million was paid during the three months ended March 31, 2025. During the three months ended March 31, 2026, the Company paid an additional $2.8 million to settle its outstanding contingent consideration which was determined based on the achievement of specified targets. The acquisition of Catapult Health was accounted for as a business combination. Catapult Health is included as a component of the Company's Integrated Care reporting segment.

The purchase price allocations for the Catapult Health acquisition include $12.7 million for identifiable intangible assets and $59.1 million for goodwill. The Company concluded that $9.4 million of the intangible and $43.2 million of the goodwill are tax deductible.

Concurrent with the closing of the acquisition of Catapult Health in the three months ended March 31, 2025, the Company performed goodwill impairment tests on its Integrated Care reporting unit and determined that the carrying value of the reporting unit continued to exceed its fair value and, thus, recorded a full impairment of the $59.1 million of acquired goodwill.

On August 8, 2025, Teladoc Health acquired full ownership of Telecare Australia Pty Ltd ("Telecare"). Including closing adjustments, the Company paid $16.6 million, which is net of $1.1 million of cash acquired. The acquisition of Telecare was accounted for as a business combination. Telecare is included as a component of the Company's Integrated Care reporting segment.

The purchase price allocations for the Telecare acquisition include $6.3 million for identifiable intangible assets and $12.6 million for goodwill. None of the goodwill is deductible for tax purposes.

Concurrent with the closing of the acquisition of Telecare in the three months ended September 30, 2025, the Company performed goodwill impairment tests on its Integrated Care reporting unit and determined that the carrying value of the reporting unit continued to exceed its fair value and, thus, recorded a full impairment of the $12.6 million of acquired goodwill.

**<u>Asset Acquisition</u>**

On April 30, 2025, Teladoc Health acquired Uplift Health Technologies, Inc. ("Uplift") by paying $29.6 million in cash. The Company subsequently accrued an additional $12.7 million that it expects it will pay during the year ending December 31, 2026 based on the achievement of certain specified targets. This transaction was accounted for as an asset acquisition since the acquired intangible asset, reflected in client and other relationships, represented substantially all of the gross assets acquired. All revenue and expense recognized following the acquisition date related to Uplift are included as a component of the Company's BetterHelp reporting segment.

**<u>Other Investments</u>**

In the three months ended March 31, 2025, Teladoc Health paid $27.0 million to acquire shares of common and preferred stock in a private company. In addition, the Company received warrants subject to certain vesting conditions that would allow for the purchase of additional preferred stock of the private company. This investment is included in "Other assets" in the Company's Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025.

**Note 7. Goodwill**

Goodwill consisted of the following (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **Integrated<br>Care** | **BetterHelp** | **Total** |
| Balance as of March 31, 2026 and December 31, 2025 | $— | $283190 | $283190 |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

As of March 31, 2026, goodwill was $283.2 million, which all related to the BetterHelp reporting unit. During the three months ended March 31, 2026, the Company's market capitalization remained below its carrying or book value. While this factor is considered in the Company's assessment of potential impairment indicators, the Company did not identify any additional events or changes in circumstances that would indicate it is more likely than not that the fair value of the BetterHelp reporting unit is below its carrying value. As a result, no interim impairment test was required. The Company will continue to monitor and evaluate events and circumstances, including a sustained decrease in the Company's share price, and should any change, it could require further testing of the goodwill, which may result in an impairment of the BetterHelp reporting unit's goodwill. Additionally, if the carrying value of the Integrated Care reporting unit exceeds its fair value as of the date of any future business combinations, future business combinations that would be part of the Integrated Care reporting unit could result in goodwill impairment charges.

**Note 8. Intangible Assets, Net and Certain Cloud Computing Costs**

Intangible assets, net consisted of the following (dollars in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Useful<br>Life** | **Gross Value** | **Accumulated<br>Amortization** | **Net Carrying<br>Value** | **Weighted<br>Average<br>Remaining<br>Useful Life<br>(Years)** |
| **March 31, 2026** | | | | | |
| Client and other relationships | &nbsp;&nbsp;2 to 20 years | $1523782 | $(631490) | $892292 | 10.1 |
| Trademarks | &nbsp;&nbsp;2 to 15 years | 271848 | (236537) | 35311 | 1.1 |
| Capitalized software development costs | &nbsp;&nbsp;3 to 5 years | 692298 | (452662) | 239636 | 2.0 |
| Acquired technology | &nbsp;&nbsp;4 to 7 years  | 330942 | (262996) | 67946 | 1.6 |
| Intangible assets, net |  | $2818870 | $(1583685) | $1235185 | 7.8 |
| **December 31, 2025** |  |  |  |  |  |
| Client and other relationships | &nbsp;&nbsp;2 to 20 years | $1525815 | $(602572) | $923243 | 10.3 |
| Trademarks | &nbsp;&nbsp;2 to 15 years | 272269 | (226370) | 45899 | 1.3 |
| Capitalized software development costs | &nbsp;&nbsp;3 to 5 years | 665631 | (416448) | 249183 | 2.0 |
| Acquired technology | &nbsp;&nbsp;4 to 7 years | 331973 | (253211) | 78762 | 1.8 |
| Intangible assets, net |  | $2795688 | $(1498601) | $1297087 | 7.9 |

---

The following table presents the Company's amortization of intangible assets expense by component (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Amortization of acquired intangibles | $51751 | $42411 |
| Amortization of capitalized software development costs | 38075 | 41893 |
| Amortization of intangible assets | $89826 | $84304 |

---

During the three months ended December 31, 2025, the Company initiated a strategy to transition the remainder of its chronic condition management Clients and members to the Teladoc Health brand by December 31, 2026. In connection with the brand strategy, the Company has decreased the remaining useful life of the related trademarks asset, which increased amortization expense for the three months ended March 31, 2026 by $7.7 million, or $0.04 per share, and will increase amortization expense for the full year ending December 31, 2026 by $30.7 million.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

Periodic amortization of intangible assets that will be charged to expense over the remaining life of the intangible assets as of March 31, 2026 was as follows (in thousands):

---

| | |
|:---|:---|
| Years Ending December 31, |  |
| Remainder of 2026 | $261630 |
| 2027 | 245724 |
| 2028 | 147853 |
| 2029 | 107347 |
| 2030 and thereafter | 472631 |
|  | $1235185 |

---

Net cloud computing costs, which are primarily related to the implementation of the Company's customer relationship management ("CRM") and enterprise resource planning ("ERP") systems, are recorded in "Other assets" within the Company's Condensed Consolidated Balance Sheets. As of March 31, 2026 and December 31, 2025, those costs were $44.6 million and $45.4 million, respectively. The associated expense for cloud computing costs, which is recorded in general and administration expense, was $2.6 million and $1.9 million for the three months ended March 31, 2026 and 2025, respectively. The capitalized cloud computing implementation costs are amortized over the shorter of the term of the related cloud computing arrangement or the period of benefit from the right to access the hosted software. The amortization period will be periodically reassessed to determine if it continues to be reasonable.

**Note 9. Accrued Expenses and Other Current Liabilities**

Accrued expenses and other current liabilities consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Franchise, sales, other taxes, and compliance related liabilities | $61558 | $50428 |
| Marketing and advertising | 31887 | 26707 |
| Client performance guarantees and accrued rebates | 20352 | 19734 |
| Professional fees | 14101 | 9868 |
| Consulting fees/provider fees | 13970 | 13790 |
| Contingent consideration related to acquisitions (1) | 12675 | 15523 |
| Operating lease liabilities—current | 10501 | 11037 |
| Information technology | 9767 | 12174 |
| Insurance | 8455 | 7719 |
| Lease abandonment obligation—current | 4510 | 4443 |
| Staff augmentation | 4453 | 5301 |
| Interest payable | 4167 | 1042 |
| Other | 36896 | 20442 |
| Total | $233292 | $198208 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;See Note 6. "Acquisitions" for further information.

**Note 10. Debt**

**Outstanding Convertible Senior Notes**

At March 31, 2026, the Company's outstanding senior notes consisted of $1.0 billion aggregate principal amount of 1.25% convertible senior notes due 2027 (the "2027 Notes"), issued on May 19, 2020 for net proceeds to the Company of $975.9 million after deducting offering costs of approximately $24.1 million.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

The following table presents certain terms of the 2027 Notes that were outstanding as of March 31, 2026:

---

| | |
|:---|:---|
| | **2027 Notes** |
| Principal Amount Outstanding as of March 31, 2026 (in thousands) | $1000000 |
| Interest Rate Per Year | 1.25% |
| Fair Value as of March 31, 2026 (in thousands) (1) | $961000 |
| Fair Value as of December 31, 2025 (in thousands) (1) | $950000 |
| Maturity Date | June 1, 2027 |
| Optional Redemption Date | June 5, 2024 |
| Conversion Date | December 1, 2026 |
| Conversion Rate Per $1,000 Principal Amount as of March 31, 2026 | 4.1258 |
| Remaining Contractual Life as of March 31, 2026 | 1.2 years |

---

(1)The Company estimates the fair value of its 2027 Notes utilizing market quotations for debt that have quoted prices in active markets. Since the 2027 Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities. The 2027 Notes would be classified as Level 2 within the fair value hierarchy, as defined in Note 2. "Basis of Presentation and Principles of Consolidation."

The 2027 Notes are unsecured obligations of the Company and rank senior in right of payment to the Company's indebtedness that is expressly subordinated in right of payment to such 2027 Notes; equal in right of payment to the Company's liabilities that are not so subordinated; effectively junior in right of payment to any of the Company's secured indebtedness to the extent of the value of the assets securing such indebtedness (including the Credit Agreement described below); and structurally junior to all indebtedness and other liabilities incurred by the Company's subsidiaries.

Holders may convert all or any portion of their 2027 Notes in integral multiples of $1,000 principal amount, at their option, at any time prior to the close of business on the business day immediately preceding the applicable conversion date only under the following circumstances:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• during any quarter (and only during such quarter), if the last reported sale price of the shares of the Company's common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding quarter is greater than or equal to 130% of the conversion price for the 2027 Notes on each applicable trading day;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• during the five business day period after any 10 consecutive trading day period in which the trading price was less than 98% of the product of the last reported sale price of Company's common stock and the conversion rate for the 2027 Notes on each such trading day;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon the occurrence of specified corporate events described under the applicable indenture; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if the Company calls the 2027 Notes for redemption, at any time until the close of business on the second business day immediately preceding the redemption date.

On or after the applicable conversion date, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of the 2027 Notes, regardless of the foregoing circumstances.

The 2027 Notes are convertible into shares of the Company's common stock at the applicable conversion rate shown in the table above. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company's common stock or a combination thereof, at the Company's election. If the Company elects to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company's common stock, the amount of cash and shares of the Company's common stock due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 25 consecutive trading day observation period.

The Company may redeem for cash all or part of the 2027 Notes, at its option, on or after the applicable optional redemption date shown in the table above if the last reported sale price of its common stock exceeds 130% of the

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately preceding the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling the 2027 Notes for redemption on or after the applicable optional redemption date will constitute a make-whole fundamental change with respect to the 2027 Notes, in which case the conversion rate applicable to the conversion of the 2027 Notes, if it is converted in connection with the redemption, will be increased in certain circumstances as described in the applicable indenture.

The Company accounts for the 2027 Notes at amortized cost within the liability section of its Condensed Consolidated Balance Sheets. The Company has reserved an aggregate of 4.1 million shares of common stock for the 2027 Notes.

The net carrying values of the 2027 Notes consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Principal | $1000000 | $1000000 |
| Less: Debt discount (1) | (4189) | (5075) |
| Net carrying amount | $995811 | $994925 |

---

(1)Included in the accompanying Condensed Consolidated Balance Sheets within Convertible senior notes, net and amortized to interest expense over the expected life of the notes using the effective interest rate method.

The following table sets forth the total interest expense recognized for the 2027 Notes (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Contractual interest expense | $3125 | $3125 |
| Amortization of debt discount | 886 | 872 |
| Total | $4011 | $3997 |
| Effective interest rate | 1.6% | 1.6% |

---

***Revolving Credit Facility***

On July 17, 2025 (the "Effective Date"), the Company entered into a credit agreement (the "Credit Agreement") that provides for a five-year, $300.0 million senior secured revolving credit facility (the "Revolving Credit Facility").

Interest rates under the Revolving Credit Facility are variable and are equal to the euro interbank offered rate, the Sterling Overnight Index Average Reference Rate, the Secured Overnight Financing Rate ("Adjusted Term SOFR") or the Canadian Overnight Repo Rate Average, in each case, plus a margin of 2.75% to 3.25% per annum based on the Company's secured net leverage ratio, or, at the Company's option, at a base reference rate equal to the highest of (a) the federal funds rate plus 0.50%, (b) the rate of interest last quoted by the administrative agent of the Revolving Credit Facility (the "Administrative Agent") as its "base rate" and (c) the one-month Adjusted Term SOFR plus 1.00%, plus a margin of 1.75% to 2.25% per annum based on the Company's secured net leverage ratio.

The Company pays customary agency fees and a commitment fee based on the daily unused portion of the Revolving Credit Facility at a rate of 0.50% per annum. The Revolving Credit Facility is not subject to amortization and will mature on the fifth anniversary of the Effective Date.

In connection with the closing of the Credit Agreement, the Company paid $4.1 million in fees that are being amortized over the life of the Credit Agreement. At March 31, 2026, $3.5 million of the fees remain unamortized and are being carried as an asset.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

The Company's obligations under the Credit Agreement are unconditionally guaranteed by all material domestic and foreign wholly-owned subsidiaries of the Company (the "Subsidiary Guarantors" and together with the Company, the "Obligors"), with customary exceptions.

On the Effective Date, each of the Obligors and the Administrative Agent entered into a pledge and security agreement, pursuant to which the Obligors granted a security interest in substantially all of their respective assets, in each case, subject to customary exceptions and exclusions.

***Compliance with Debt Covenants***

The Credit Agreement contains customary representations and warranties, affirmative covenants, negative covenants and events of default. The Credit Agreement also contains financial covenants that are tested on the last day of each of the Company's fiscal quarters. These financial covenants include a maximum secured net leverage ratio of 3.5:1, subject to a 4.0:1 covenant holiday following certain permitted acquisitions or permitted collaborations, and a minimum consolidated interest coverage ratio of 3.0:1. As of March 31, 2026, the Company was in compliance with these covenants.

As of March 31, 2026, the Company had approximately $3.4 million of outstanding letters of credit under the Revolving Credit Facility, leaving approximately $296.6 million available for borrowing, from which the Company had not drawn.

**Note 11. Restructuring**

Restructuring charges may include employee severance and related separation costs and lease related costs associated with office space reductions. Employee severance and related separation costs are recognized when a liability is incurred and the amount to be paid is both probable and reasonably estimated.

The Company recorded $12.0 million of restructuring costs during the three months ended March 31, 2026, of which $11.0 million was related to employee transition, severance, employee benefits, and related costs and $1.0 million was related to costs associated with office space reductions, including $0.2 million of right-of-use asset impairment charges.

The Company recorded $4.3 million of restructuring costs during the three months ended March 31, 2025, of which $3.6 million was related to employee transition, severance, employee benefits, and related costs and $0.7 million was related to costs associated with office space reductions, including $0.2 million of right-of-use asset impairment charges.

The Company continues to expect that pre-tax restructuring costs for the year ending December 31, 2026 will remain within the range of $15.0 million to $20.0 million. The remaining charges will primarily relate to employee transition, severance, employee benefits, and other costs, including costs associated with office space reductions.

The portion of these expenses that are to be settled by cash disbursements was accounted for as a restructuring liability under the line item "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheets.

The table below summarizes the accrual and charges incurred and cash payments made with respect to the Company's restructurings, with the severance related portion included in the line item "Accrued compensation" and the lease termination and other related portion included in the line item "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheet as of March 31, 2026 (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **Restructuring Plan** | **Restructuring Plan** | **Restructuring Plan** |
| | **Severance** | **Lease Termination** | **Total** |
| **Accrued Balance, December 31, 2025** | $2321 | $4443 | $6764 |
| Additions | 11009 | 855 | 11864 |
| Cash payments | (8762) | (788) | (9550) |
| **Accrued Balance, March 31, 2026** | $4568 | $4510 | $9078 |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Note 12. Stock-based Compensation**

The Company regularly issues share-based compensation to its employees and directors who are not employees of the Company. The accounting guidance for share-based compensation requires measurement of compensation cost for share-based awards at fair value and recognition of compensation cost over the service period. For a full description of the Company's stock-based compensation programs, refer to Note 14 of the Company's financial statements included in the Company's 2025 Form 10-K.

In the three months ended March 31, 2026, the Company granted a portion of its employees awards in the form of restricted stock units ("RSUs") and performance stock units ("PSUs"). The total number of units granted was approximately 7.1 million and the aggregate fair value of the awards was $37.3 million. A portion of the awards granted consisted of RSUs vesting over a three year period, with one-third vesting on the first anniversary of the grant and with the remainder vesting quarterly thereafter. A smaller portion of the awards granted consisted of PSUs subject to the achievement of specific performance criteria that will time-vest over a three year period, whereas the expense will be recognized on an accelerated tranche-by-tranche basis.

The following table reflects stock-based compensation expense by award type for the indicated periods (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Options | $208 | $1068 |
| RSUs | 12588 | 22170 |
| PSUs | 1495 | 1530 |
| Employee stock purchase plan | 320 | 395 |
| Total stock-based compensation expense | $14611 | $25163 |

---

Total compensation costs for stock-based awards were recorded for the indicated periods as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately) | $347 | $573 |
| Advertising and marketing | 860 | 1503 |
| Sales | 2077 | 4259 |
| Technology and development | 2727 | 5785 |
| General and administrative | 8600 | 13043 |
| Total stock-based compensation expense | 14611 | 25163 |
| Capitalized stock-based compensation | 530 | 2577 |
| Total stock-based compensation | $15141 | $27740 |

---

As of March 31, 2026, the Company had unrecognized compensation cost related to outstanding stock-based award as follows (dollars in thousands):

---

| | | |
|:---|:---|:---|
| **Award Type** | **Unearned Compensation** | **Weighted Average Remaining Life<br>(Years)** |
| Options | $977 | 1.6 |
| RSUs | $70576 | 2.1 |
| PSUs | $14519 | 2.6 |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Note 13. Provision for Income Taxes**

The Company recorded an income tax expense of $3.0 million for the three months ended March 31, 2026 and an income tax benefit of $18.3 million for the same period in 2025. The tax expense for the three months ended March 31, 2026 resulted primarily from an increase in the valuation allowance. The tax benefit in the three months ended March 31, 2025 resulted primarily from a discrete benefit of $20.1 million related to completion of a research and development tax credit study.

**Note 14. Commitments and Contingencies**

***Commitments***

The Company has contractual obligations to make future payments related to its outstanding convertible senior notes and its long-term operating leases.

***Legal Matters***

From time to time, Teladoc Health is involved in various litigation matters arising in the normal course of business, including the matters described below. The Company consults with legal counsel on those issues related to litigation and seeks input from other experts and advisors with respect to such matters. Estimating the probable losses or a range of probable losses resulting from litigation, government actions, and other legal proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, may involve discretionary amounts, present novel legal theories, are in the early stages of the proceedings, or are subject to appeal. Whether any losses, damages, or remedies ultimately resulting from such matters could reasonably have a material effect on the Company's business, financial condition, results of operations, or cash flows will depend on a number of variables, including, for example, the timing and amount of such losses or damages (if any) and the structure and type of any such remedies. As of the date of these financial statements, Teladoc Health's management does not expect any litigation matter to have a material adverse impact on its business, financial condition, results of operations, or cash flows. The Company has recorded accruals for certain matters where losses are considered probable and reasonably estimable.

On June 6, 2022, a purported securities class action complaint (Schneider v. Teladoc Health, Inc., *et al.*) was filed in the U.S. District Court for the Southern District of New York against the Company and certain of the Company's officers. The complaint was brought on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company's common stock during the period October 28, 2021 through April 27, 2022. The complaint asserted violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder based on allegedly false or misleading statements and omissions with respect to, among other things, the Company's business, operations, and prospects. The complaint seeks certification as a class action and unspecified compensatory damages plus interest and attorneys' fees. On August 2, 2022, a duplicative purported securities class action complaint (De Schutter v. Teladoc Health, Inc., *et al.*) was filed in the U.S. District Court for the Eastern District of New York, which was consolidated with the Schneider case in the Southern District court under the caption In re Teladoc Health, Inc. Securities Litigation. The lead plaintiff subsequently filed amended complaints that expanded the alleged class period to February 11, 2021 to July 27, 2022. On July 5, 2023, the court granted the defendants' motion to dismiss the complaint, and on September 24, 2024 the U.S. Court of Appeals for the Second Circuit affirmed in part, and vacated in part, the Southern District court's dismissal and remanded for further proceedings. On March 21, 2025, the court granted the defendant's renewed motion to dismiss, and on July 25, 2025 the lead plaintiff filed an appeal of the Southern District Court's dismissal in the United States Court of Appeals for the Second Circuit. The Company believes that it has substantial defenses, and the Company and its named officers intend to defend the lawsuit vigorously.

There have been multiple putative class-action lawsuits filed against the Company's subsidiary BetterHelp in connection with the consent order that BetterHelp entered into with the U.S. Federal Trade Commission in July 2023. The actions have been filed in California federal and state courts and in Canada. The cases are substantially similar, involving allegations of misleading patients as to BetterHelp's use of patient data and associated alleged violations of law involving privacy, advertising, contract, and tort. The Company believes that it has substantial defenses, and the Company intends to defend the lawsuits vigorously.

On February 13, 2023, Data Health Partners, Inc. ("Data Health Partners") filed a lawsuit against the Company in the U.S. District Court for the District of Delaware alleging that certain of the Company's products, including its blood glucose meter, infringe upon certain patents held by Data Health Partners and seeking unspecified damages, attorney's fees

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

and costs. The Company believes that it has substantial defenses, and the Company intends to defend the lawsuit vigorously.

On May 17, 2024, a purported securities class action complaint (Stary v. Teladoc Health, Inc., *et al.*) was filed in the U.S. District Court for the Southern District of New York against the Company and certain of the Company's current and former officers. The complaint was brought on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company's common stock during the period November 2, 2022 through February 20, 2024. The complaint asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder based on allegedly false or misleading statements and omissions with respect to, among other things, the Company's advertising spend on BetterHelp. The complaint seeks certification as a class action and unspecified compensatory damages plus interest and attorneys' fees. On July 15, 2024, a duplicative purported securities class action complaint (Waits v. Teladoc Health, Inc., *et al.*) was filed in the U.S. District Court for the Southern District of New York. The claims and parties in Waits were substantially similar to those in Stary, and the Stary and Waits actions were consolidated. On December 10, 2024, the District Court appointed co-lead plaintiffs, and, on February 24, 2025 the lead plaintiffs filed an amended complaint that asserts Exchange Act claims for a putative class of shareholders who purchased or acquired stock between July 26, 2023 and February 20, 2024. On March 31, 2026, the District Court granted in part and denied in part the Company's motion to dismiss the amended complaint. The Company believes that it has substantial defenses, and the Company and its named officers intend to defend the lawsuits vigorously.

On June 18, 2024, a verified shareholder derivative complaint (Roy v. Gorevic, *et al.*) was filed in the U.S. District Court for the Southern District of New York against the Company as a nominal defendant and certain of the Company's current and former officers and directors. The complaint asserts violations of Sections 10(b) and 14(a) of the Securities Exchange Act of 1934, breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, waste of corporate assets, gross mismanagement and abuse of control in connection with factual assertions similar to those in the purported securities class action complaint described in the preceding paragraph. The complaint seeks damages to the Company allegedly sustained as a result of the acts and omissions of the named officers and directors and seeks an order directing the Company to reform and improve the Company's corporate governance. On October 4, 2024 the parties agreed, and the Court ordered, to stay all proceedings until any motion to dismiss filed in the purported securities class action complaint described above is granted with prejudice and any appeals therefrom are resolved, or any defendant files an answer in the purported securities class action complaint described above. On October 1, 2024, a duplicative verified stockholder derivative complaint (Brigman, *et al.* v. Daniel, *et al.*) was filed in the U.S. District Court for the Southern District of New York. The claims and parties in Brigman are substantially similar to those in Roy, and also alleges insider trading violations and misappropriation of information against certain defendants. On April 7, 2025 the parties agreed, and the Court ordered, to stay all proceedings until any motion to dismiss filed in the purported securities class action complaint described above is granted with prejudice and any appeals therefrom are resolved, or any defendant files an answer in the purported securities class action complaint described above. On April 17, 2026, April 27, 2026, and April 28, 2026 duplicative verified stockholder derivative complaints (Richey v. Gorevic, *et al.,* Vrana v. Paulus, *et al.*, and North v. Daniel, *et al.*, respectively) were filed in the U.S. District Court for the Southern District of New York. The claims and parties in Richey, Vrana and North are substantially similar to those in Roy and Brigman. The named directors and officers have not yet responded to the complaints.

**Note 15. Segments**

ASC Subtopic 280-10, *"Segment Reporting,"* establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance. The Company's Chief Executive Officer is the CODM and is responsible for reviewing financial information presented on a segment basis for purposes of making operating decisions and assessing financial performance.

The CODM measures and evaluates segments based on segment operating revenues, segment expenses, and Adjusted EBITDA. The CODM reviews annual-operating-plan-to-actual variances for these measures on a regular basis to assess the performance of the segments and to make decisions about allocating resources. The Company does not include the following items in segment expenses and Adjusted EBITDA: provision for income taxes; interest income; interest expense; other expense (income), net; depreciation of property and equipment; amortization of intangible assets; restructuring costs; acquisition, integration, and transformation charges; goodwill impairment; and stock-based compensation. Although these amounts are excluded from segment Adjusted EBITDA, they are included in reported consolidated net loss and are included in the reconciliations that follow.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

The Company's computation of segment Adjusted EBITDA may not be comparable to other similarly titled metrics computed by other companies because all companies do not calculate segment Adjusted EBITDA in the same fashion.

Operating revenues and expenses directly associated with each segment are included in determining its operating results. Other expenses that are not directly attributable to a particular segment are based upon allocation methodologies, including the following: revenue, headcount, time and other relevant usage measures, and/or a combination of such.

The Company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis.

The CODM does not review any information regarding total assets on a segment basis. Segments do not record intersegment revenues, and, accordingly, there is none to be reported. The accounting policies for segment reporting are the same as for the Company as a whole.

The following tables present the financial results of the Company's reportable segments, along with reconciliations of the segments' total consolidated Adjusted EBITDA to the consolidated net loss for the periods indicated (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| **Three Months Ended March 31, 2026** | **Integrated Care** | **BetterHelp** | **Consolidated** |
| Revenue | $395445 | $218400 | $613845 |
| Cost of revenue, exclusive of depreciation, amortization, and stock-based compensation (1) | 135873 | 61305 |  |
| Advertising and marketing, exclusive of stock-based compensation (1) | 33914 | 116752 |  |
| Other segment expenses (2) | 169381 | 38451 |  |
| Adjusted EBITDA | $56277 | $1892 | 58169 |
| Less adjustments to reconcile to consolidated net loss: |  |  |  |
| Stock-based compensation |  |  | 14611 |
| Acquisition, integration, and transformation costs |  |  | 1064 |
| Restructuring costs |  |  | 11975 |
| Amortization of intangible assets |  |  | 89826 |
| Depreciation of property and equipment |  |  | 2461 |
| Other expense (income), net |  |  | 196 |
| Interest expense |  |  | 5368 |
| Interest income |  |  | (6490) |
| Loss before provision for income taxes |  |  | (60842) |
| Provision for income taxes |  |  | 2995 |
| Net loss |  |  | $(63837) |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| **Three Months Ended March 31, 2025** | **Integrated Care** | **BetterHelp** | **Consolidated** |
| Revenue | $389468 | $239901 | $629369 |
| Cost of revenue, exclusive of depreciation, amortization, and stock-based compensation (1) | 131008 | 65248 |  |
| Advertising and marketing, exclusive of stock-based compensation (1) | 33710 | 132972 |  |
| Other segment expenses (2) | 174371 | 33967 |  |
| Adjusted EBITDA | $50379 | $7714 | 58093 |
| Less adjustments to reconcile to consolidated net loss: |  |  |  |
| Stock-based compensation |  |  | 25163 |
| Goodwill impairment |  |  | 59138 |
| Acquisition, integration, and transformation costs |  |  | 2188 |
| Restructuring costs |  |  | 4347 |
| Amortization of intangible assets |  |  | 84304 |
| Depreciation of property and equipment |  |  | 3564 |
| Other expense (income), net |  |  | (2435) |
| Interest expense |  |  | 5765 |
| Interest income |  |  | (12674) |
| Loss before provision for income taxes |  |  | (111267) |
| Provision for income taxes |  |  | (18255) |
| Net loss |  |  | $(93012) |

---

(1)The significant segment expense categories and amounts align with the information that is regularly provided to the CODM.

(2)Other segment expenses for the corresponding reportable segment includes sales expenses, technology and development expenses, and general and administrative expenses, each exclusive of stock-based compensation.

Geographic data for long-lived assets (representing property and equipment, net) were as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| United States | $21283 | $22796 |
| International | 4995 | 4176 |
| Total long-lived assets | $26278 | $26972 |

---

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Special Note Regarding Forward-Looking Statements**

Many statements made in this Quarterly Report on Form 10-Q that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipates," "believes," "suggests," "targets," "projects," "plans," "expects," "future," "intends," "estimates," "predicts," "potential," "may," "will," "should," "could," "would," "likely," "foresee," "forecast," "continue" and other similar words or phrases, as well as statements in the future tense to identify these forward-looking statements. These forward-looking statements and projections are contained throughout this Form 10-Q, including the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." We base these forward-looking statements or projections on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances and at such time. As you read and consider this Form 10-Q, you should understand that these statements are not guarantees of performance or results. The forward-looking statements and projections are subject to and involve risks, uncertainties, and assumptions and you should not place undue reliance on these forward-looking statements or projections. Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements and projections. Factors that may materially affect such forward-looking statements and projections include, but are not limited to, the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K") and in our other reports and U.S. Securities and Exchange Commission ("SEC") filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this Form 10-Q. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should evaluate all forward-looking statements made in this Form 10-Q in the context of these risks and uncertainties.

**Overview**

Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as "Teladoc Health," the "Company," or "we." In June 2025, the Company relocated its principal executive office from Purchase, New York to New York, New York. Teladoc Health is the global leader in virtual care.

More than 20 years ago, we were founded on a simple, yet revolutionary idea: that everyone should have access to the best healthcare, anywhere in the world on their terms.

Our mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. Today, we are transforming virtual care into a catalyst for how better health happens around the world. We connect patients, care providers, healthcare platforms and partners to provide more complete and personalized care. Through our unique technology, breadth of services and depth of clinical expertise, we are delivering and orchestrating care in order to improve health outcomes and reduce healthcare costs around the world.

The impact that the imposition of tariffs and changes to global trade policies will have on our consolidated results of operations is uncertain. We expect tariffs on goods imported into the U.S. from Canada, Mexico, and China, and other countries upon which tariffs may be imposed, to continue to be met with retaliatory tariffs from those countries which would impact our consolidated results of operations as we import components for assembling welcome kits, refill kits, and replacement components for our chronic care management solutions and virtual care devices manufactured for sale or lease as part of our hosted virtual care platform solution. The extent and duration of tariffs and the resulting impact on macroeconomic conditions and on our business are uncertain and may depend on various factors, including negotiations between the U.S. and affected countries, retaliation imposed by other countries, tariff exemptions, negative sentiment toward U.S. companies and products, and availability of lower cost inputs that may be sourced domestically or in other countries with no or lower tariffs. We will continue to evaluate the nature and extent of the impact to our business and consolidated results of operations. For further information, see "Risk Factors—We depend on a limited number of third-party suppliers for certain components of our medical devices, and the loss of any of these suppliers, or their inability to

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

provide us with an adequate supply of materials, could harm our business," and "—Our international operations pose certain political, legal and compliance, operational, regulatory, economic, and other risks to our business that may be different from or more significant than risks associated with our domestic operations, and our exposure to these risks is expected to increase" included in our 2025 Form 10-K.

**Key Factors Affecting Our Performance**

We believe that our future performance will depend on many factors, including the following:

As it relates to the Integrated Care segment:

*Number of U.S. Integrated Care Members.* U.S. Integrated Care members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period. Individuals who have paid access fees offer a greater margin than those who have visit fee only arrangements and, over time, the mix of those who have paid access fees as compared to those who have visit fee only arrangements has declined. Our revenue growth rate and long-term profitability are affected by our ability to increase cross selling capability among our existing members over time because we derive a substantial portion of our revenue from access and other fees via Client contracts that provide members access to the THMG Association professional provider network in exchange for a contractual based periodic fee. Therefore, we believe that our ability to add new members and retain existing members, and to increase utilization and penetration further into existing and new health plan and employer Clients is a key indicator of our increasing market adoption, the growth of our business, and our future revenue potential. We further believe that increasing our membership is an integral objective that will provide us with the ability to continually innovate our services and support initiatives that will enhance members' experiences. However, certain health plans that have historically promoted our services to our employer Clients have developed, and may in the future continue to develop, solutions that replicate our services or offer competitive services at discounted prices to our current or prospective Clients, which could result in a loss of members. For further information, see "Risk Factors—Risks Related to Our Business and Industry—We operate in a competitive industry, and if we are not able to compete effectively, our business, financial condition, and results of operations will be harmed," and "—A significant portion of our revenue comes from a limited number of Clients, the loss of which could have a material adverse effect on our business, financial condition and results of operations" included in our 2025 Form 10-K. U.S. Integrated Care members decreased by 1.3 million, or 1%, to 101.2 million at March 31, 2026, compared to the same period in 2025.

*Chronic Care Program Enrollment*. Chronic care program enrollment represents the total number of enrollees across our suite of chronic care programs at the end of a given period. Our chronic care program enrollments are one of the key components of our virtual care platform that we believe positions us to drive greater engagement with our platforms and increase revenue. Chronic care program enrollment increased to 1.197 million, or 4%, at March 31, 2026, compared to 1.151 million at March 31, 2025.

*Average Monthly Revenue Per U.S. Integrated Care Member*. Average monthly revenue per U.S. Integrated Care member measures the average monthly amount of global revenue that we generate from a U.S. Integrated Care member for a particular period. It is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care members during the applicable period. Approximately 21% of total Integrated Care revenues relates to international and hospital and health systems for which membership is not considered as a management metric. We believe that our ability to increase the revenue generated from each member over time is also a key indicator of our increasing market adoption and future revenue growth potential. Average monthly revenue per U.S. Integrated Care member was $1.30 in the three months ended March 31, 2026, compared to $1.27 in the same period in 2025. The change in average monthly revenue versus the prior period is reflective of the decrease in members and the mix of their fees.

As it relates to the BetterHelp segment:

*BetterHelp Paying Users.* BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy and psychiatry services during the applicable period, including both those who pay directly out-of-pocket and those who utilize their insurance coverage. We believe that our ability to add new paying users and retain existing users is a key indicator of the market adoption of BetterHelp, the growth of this segment, and future revenue potential. Effectively reaching potential paying users through various advertising channels remains critical to our success. BetterHelp Paying Users decreased by 9% to 0.361 million for the three months ended March 31, 2026, compared to 0.397 million for the three months ended March 31, 2025.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

As it relates to the Company:

*Seasonality.* Our business has historically been subject to seasonality. In our Integrated Care segment, a concentration of our new Client contracts have an effective date of January 1 as a result of many Clients' introduction of new services at the start of each calendar year. Therefore, while membership increases, utilization and enrollment rates are dampened until service delivery ramps up over the course of the year. In addition, as a result of seasonal cold and flu trends, we historically have experienced our highest level of visit and other fee revenue during the first and fourth quarters of each year.

Due to the higher cost of customer acquisition during the end-of-year holiday season, our BetterHelp segment has historically reduced marketing activity during the fourth quarter. As a result of this dynamic, we have typically experienced fewer new member additions and strong operating income performance in the fourth quarter. Conversely, as marketing activity typically resumes at the start of the year, we typically experience weak operating income performance during the first quarter as new customer acquisition and revenue growth lags marketing spend.

**Critical Accounting Estimates and Policies**

Our discussion and analysis of our results of operations, liquidity and capital resources are based on our condensed consolidated financial statements which have been prepared in conformity with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities.

As of March 31, 2026, goodwill was $283.2 million, which all related to the BetterHelp segment. During the three months ended March 31, 2026, our market capitalization remained below the Company's carrying or book value. While this factor is considered in our assessment of potential impairment indicators, we did not identify any additional events or changes in circumstances that would indicate it is more likely than not that the fair value of the BetterHelp reporting unit is below its carrying value. As a result, no interim impairment test was required. We will continue to monitor and evaluate events and circumstances, including a sustained decrease in our share price, and should any change, it could require further testing of the goodwill, which may result in an impairment of the BetterHelp reporting unit's goodwill.

On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, business combinations, goodwill and other intangible assets, income taxes, and other items. We base our estimates on historical and anticipated results and trends and on various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results may differ from our estimates and could have a significant adverse effect on our results of operations and financial position. For a discussion of our critical accounting estimates and policies see Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the 2025 Form 10-K.

**Non-GAAP Financial Measures**

To supplement our financial information presented in accordance with GAAP, we use certain non-GAAP financial measures to clarify and enhance an understanding of past performance, which include Adjusted EBITDA (as defined below) and free cash flow. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance, and are commonly used by investors to evaluate our performance and that of our competitors. We further believe that these financial measures are useful to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows. We use these non-GAAP financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize Adjusted EBITDA as a key measure of our performance.

Adjusted EBITDA consists of net loss before provision for income taxes; other expense (income), net; interest income; interest expense; depreciation of property and equipment; amortization of intangible assets; restructuring costs; acquisition, integration, and transformation cost; goodwill impairments; and stock-based compensation.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.

Our use of these non-GAAP terms may vary from that of others in our industry, and other companies may calculate such measures differently than we do, limiting their usefulness as comparative measures.

Non-GAAP measures have important limitations as analytical tools and you should not consider them in isolation, and they should not be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other measures derived in accordance with GAAP. Some of these limitations are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA eliminates the impact of the provision for income taxes on our results of operations, and does not reflect other expense (income), net, interest income, or interest expense;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration, and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our ERP system. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect goodwill impairment charges; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.

In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being amortized and depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any expenditures for such replacements.

We compensate for these limitations by using these non-GAAP measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Condensed Consolidated Results of Operations**

The following table sets forth our condensed consolidated statements of operations data for the three months ended March 31, 2026 and 2025 and the dollar and percentage change between the respective periods (dollars in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | | |
| | **2026** | **2025** |<br>**Variance** |<br>**%** |
| Revenue | $613845 | $629369 | $(15524) | (2)% |
| Costs and expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 197526 | 196829 | 697 | —% |
| &nbsp;&nbsp;&nbsp;Advertising and marketing | 151527 | 168185 | (16658) | (10)% |
| &nbsp;&nbsp;&nbsp;Sales | 51276 | 48693 | 2583 | 5% |
| &nbsp;&nbsp;&nbsp;Technology and development | 67865 | 69958 | (2093) | (3)% |
| &nbsp;&nbsp;&nbsp;General and administrative | 102093 | 112774 | (10681) | (9)% |
| &nbsp;&nbsp;&nbsp;Goodwill impairment |  | 59138 | (59138) | (100)% |
| &nbsp;&nbsp;&nbsp;Acquisition, integration, and transformation costs | 1064 | 2188 | (1124) | (51)% |
| &nbsp;&nbsp;&nbsp;Restructuring costs | 11975 | 4347 | 7628 | 175% |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 89826 | 84304 | 5522 | 7% |
| &nbsp;&nbsp;&nbsp;Depreciation of property and equipment | 2461 | 3564 | (1103) | (31)% |
| Total costs and expenses | 675613 | 749980 | (74367) | (10)% |
| Loss from operations | (61768) | (120611) | 58843 | (49)% |
| Interest income | (6490) | (12674) | 6184 | (49)% |
| Interest expense | 5368 | 5765 | (397) | (7)% |
| Other expense (income), net | 196 | (2435) | 2631 | (108)% |
| Loss before provision for income taxes | (60842) | (111267) | 50425 | (45)% |
| Provision for income taxes | 2995 | (18255) | 21250 | (116)% |
| Net loss | $(63837) | $(93012) | $29175 | (31)% |
| Net loss per share, basic and diluted | $(0.36) | $(0.53) | $0.17 | (32)% |
| Adjusted EBITDA (1) | $58169 | $58093 | $76 | —% |

---

(1)Non-GAAP Financial Measure

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

The following table reconciles net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the three months ended March 31, 2026 and 2025 (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Net loss | $(63837) | $(93012) |
| Add: |  |  |
| Provision for income taxes | 2995 | (18255) |
| Other expense (income), net | 196 | (2435) |
| Interest expense | 5368 | 5765 |
| Interest income | (6490) | (12674) |
| Depreciation of property and equipment | 2461 | 3564 |
| Amortization of intangible assets | 89826 | 84304 |
| Restructuring costs | 11975 | 4347 |
| Acquisition, integration, and transformation costs | 1064 | 2188 |
| Goodwill impairment |  | 59138 |
| Stock-based compensation | 14611 | 25163 |
| Adjusted EBITDA | $58169 | $58093 |
| Integrated Care | $56277 | $50379 |
| BetterHelp | 1892 | 7714 |
| Adjusted EBITDA | $58169 | $58093 |

---

***Revenue.*** 

The following table presents revenues disaggregated by revenue source and geography for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | | |
| *(In thousands, unaudited)* | **2026** | **2025** | **Variance** | **%** |
| **Revenue by Type** |  |  |  |  |
| Access Fees | $484655 | $525736 | $(41081) | (8)% |
| Other | 129190 | 103633 | 25557 | 25% |
| Total Revenue | $613845 | $629369 | $(15524) | (2)% |
| **Revenue by Geography** |  |  |  |  |
| U.S. | $491505 | $524970 | $(33465) | (6)% |
| International | 122340 | 104399 | 17941 | 17% |
| Total Revenue | $613845 | $629369 | $(15524) | (2)% |

---

Total revenue was $613.8 million for the three months ended March 31, 2026, compared to $629.4 million for the three months ended March 31, 2025, a decrease of $15.5 million, or 2%. This decrease in revenue was driven by lower revenue in our BetterHelp segment, partially offset by higher revenue in our Integrated Care segment. The acquisitions of Catapult Health, Uplift, and Telecare increased total revenue for the three months ended March 31, 2026 by approximately 3 percentage points. Other revenue predominately includes visit fees and, to a lesser extent, revenue from the sales of our telehealth solutions for hospitals and health systems.

***Cost of Revenue (exclusive of depreciation and amortization, which are shown separately below)****.* Cost of revenue was flat at $197.5 million for the three months ended March 31, 2026, compared to $196.8 million for the three

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

months ended March 31, 2025. Comparatively higher labor costs and technology costs for the three months ended March 31, 2026 were offset by lower provider costs.

***Advertising and Marketing Expenses.*** Advertising and marketing expenses were $151.5 million for the three months ended March 31, 2026, compared to $168.2 million for the three months ended March 31, 2025, a decrease of $16.7 million, or 10%. The decrease was driven mainly by lower digital and media advertising costs.

***Sales Expenses.*** Sales expenses were $51.3 million for the three months ended March 31, 2026, compared to $48.7 million for the three months ended March 31, 2025, an increase of $2.6 million, or 5%. This increase reflects higher commissions, offset by lower employee compensation costs.

***Technology and Development Expenses.*** Technology and development expenses were $67.9 million for the three months ended March 31, 2026, compared to $70.0 million for the three months ended March 31, 2025, a decrease of $2.1 million, or 3%. The decrease primarily reflects lower employee compensation costs and travel costs, partially offset by higher professional fees and dues and subscriptions.

For the three months ended March 31, 2026 and 2025, research and development costs, which exclude amounts reflected as capitalized software development costs, were $20.2 million and $22.9 million, respectively.

***General and Administrative Expenses.*** General and administrative expenses decreased $10.7 million, or 9%, to $102.1 million for the three months ended March 31, 2026, compared to $112.8 million for the three months ended March 31, 2025. The decrease was primarily driven by lower employee compensation costs, professional fees, occupancy costs, and travel costs, partially offset by higher indirect taxes.

***Goodwill Impairments.*** We did not record a non-cash goodwill impairment charge for the three months ended March 31, 2026. In the three months ended March 31, 2025, concurrent with the completion of the acquisition of Catapult Health, we performed a goodwill impairment test on the Integrated Care reporting unit and determined that the carrying value of the reporting unit exceeded its fair value. As a result, we recognized a goodwill impairment of $59.1 million associated with the acquisition of Catapult Health. If the carrying value of the Integrated Care reporting unit exceeds its fair value as of the date of any future business combinations, the future business combinations that would be part of the Integrated Care reporting unit could result in further goodwill impairment charges.

***Acquisition, Integration, and Transformation Costs.*** Acquisition, integration, and transformation costs primarily consisted of costs to integrate and upgrade our ERP ecosystem and costs to integrate the operations of acquired businesses and were $1.1 million and $2.2 million for the three months ended March 31, 2026 and 2025, respectively.

***Restructuring Costs*.** Restructuring costs for the three months ended March 31, 2026 were $12.0 million, of which $11.0 million was for employee transition, severance, employee benefits, and related costs and $1.0 million was related to costs associated with office space reductions, including $0.2 million of right-of-use asset impairment charges.

Restructuring costs for the three months ended March 31, 2025 were $4.3 million, of which $3.6 million was for employee transition, severance, employee benefits, and related costs and $0.7 million was related to costs associated with office space reductions, including $0.2 million of right-of-use asset impairment charges.

As a result of our review of the business to drive further efficiency, better align resources, and improve profitability, we continue to expect to incur pre-tax restructuring costs under our plan in the range of $15.0 million to

$20.0 million for the year ending December 31, 2026. The charges will primarily relate to employee transition, severance, employee benefits, and other costs, including costs associated with office space reductions.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

***Amortization of Intangible Assets.*** 

The following table shows amortization of intangible assets broken down by components for the periods indicated (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | |
| | **2026** | **2025** |<br>**%** |
| Amortization of acquired intangibles | $51751 | $42411 | 22% |
| Amortization of capitalized software development costs | 38075 | 41893 | (9)% |
| Amortization of intangible assets | $89826 | $84304 | 7% |

---

Amortization of intangible assets was $89.8 million for the three months ended March 31, 2026, compared to $84.3 million for the three months ended March 31, 2025, an increase of $5.5 million, or 7%. The increase was primarily driven by higher amortization associated with the strategy to transition the remainder of our chronic condition management Clients and members to the Teladoc Health brand by December 31, 2026.

***Depreciation of Property and Equipment.*** Depreciation of property and equipment was $2.5 million for the three months ended March 31, 2026, compared to $3.6 million for the three months ended March 31, 2025, a decrease of $1.1 million, or 31%.

***Interest Income.*** Interest income consisted of interest earned on cash and cash equivalents. Interest income was $6.5 million for the three months ended March 31, 2026, compared to $12.7 million for the three months ended March 31, 2025. The decrease for the three months ended March 31, 2026 was driven by lower interest rate yields and a lower average balance of cash and cash equivalents.

***Interest Expense.*** Interest expense consisted of interest costs and the amortization of debt discounts primarily associated with the convertible senior notes. Interest expense was $5.4 million for the three months ended March 31, 2026, compared to $5.8 million for the three months ended March 31, 2025. The decrease was driven by the maturation of previously outstanding notes in the prior year.

***Other Expense (Income), net.*** Other expense (income), net was an expense of $0.2 million for the three months ended March 31, 2026, compared to an income of $2.4 million for the three months ended March 31, 2025. The change primarily reflects the impact of foreign currency exchange rate fluctuations.

***Provision for Income Taxes*.** We recorded an income tax expense of $3.0 million for the three months ended March 31, 2026 compared to an income tax benefit of $18.3 million for the three months ended March 31, 2025. The tax expense for the three months ended March 31, 2026 resulted primarily from an increase in the valuation allowance. The tax benefit in 2025 resulted primarily from a discrete benefit of $20.1 million related to completion of a research and development tax credit study.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Segment Information**

The following tables set forth the results of operations by segment for the three months ended March 31, 2026 and 2025 (dollars in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | | |
| **Integrated Care** | **2026** | **2026** | **2025** | **2025** | **Variance** | **%** |
| Revenue | $| 395445 | $| 389468 | $5977 | 2% |
| Cost of revenue, exclusive of depreciation, amortization, and stock-based compensation | 135873 | 135873 | 131008 | 131008 | 4865 | 4% |
| Advertising and marketing, exclusive of stock-based compensation | 33914 | 33914 | 33710 | 33710 | 204 | 1% |
| Other segment expenses (1) | 169381 | 169381 | 174371 | 174371 | (4990) | (3)% |
| Adjusted EBITDA | $| 56277 | $| 50379 | $5898 | 12% |
| Adjusted EBITDA Margin % | 14.2% | 14.2% | 12.9% | 12.9% |  |  |

---

(1)Other segment expenses include sales expenses, technology and development expenses, and general and administrative expenses, each exclusive of stock-based compensation.

Integrated Care total revenues increased by $6.0 million, or 2%, to $395.4 million for the three months ended March 31, 2026. The acquisitions of Catapult Health and Telecare increased Integrated Care total revenue for the three months ended March 31, 2026 by approximately 2 percentage points.

Integrated Care cost of revenue, exclusive of depreciation, amortization, and stock-based compensation, increased by $4.9 million, or 4%, to $135.9 million for the three months ended March 31, 2026. The increase was primarily driven by higher labor and provider costs.

Integrated Care advertising and marketing, exclusive of stock-based compensation, increased by $0.2 million, or 1%, to $33.9 million for the three months ended March 31, 2026, primarily reflecting higher digital and media advertising costs and professional fees, partially offset by lower employee compensation costs.

Integrated Care other segment expenses decreased by $5.0 million to $169.4 million for the three months ended March 31, 2026. The decrease was primarily driven by lower employee compensation costs, legal costs, professional fees, and infrastructure, hosting and software license costs, partially offset by higher commissions and indirect taxes.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | | |
| **BetterHelp** | **2026** | **2025** | **2025** | **Variance** | **%** |
| Consumer and Other | $205463 | $| 239901 | $(34438) | (14)% |
| Insurance Covered Services | 12937 |  |  | 12937 | n/a |
| Total Revenue | 218400 | 239901 | 239901 | (21501) | (9)% |
| Cost of revenue, exclusive of depreciation, amortization, and stock-based compensation | 61305 | 65248 | 65248 | (3943) | (6)% |
| Advertising and marketing, exclusive of stock-based compensation | 116752 | 132972 | 132972 | (16220) | (12)% |
| Other segment expenses (1) | 38451 | 33967 | 33967 | 4484 | 13% |
| Adjusted EBITDA | $1892 | $| 7714 | $(5822) | (75)% |
| Adjusted EBITDA Margin % | 0.9% | 3.2% | 3.2% |  |  |

---

n/a - not applicable

(1)Other segment expenses include sales expenses, technology and development expenses, and general and administrative expenses, each exclusive of stock-based compensation.

BetterHelp total revenue decreased by $21.5 million, or 9%, to $218.4 million for the three months ended March 31, 2026, driven by a 9% decrease in average monthly paying users. The acquisition of Uplift increased BetterHelp total

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

revenue by approximately 6 percentage points. Within BetterHelp, Consumer and Other primarily includes revenue from BetterHelp Paying Users that pay for services directly out-of-pocket while Insurance Covered Services reflects revenue from BetterHelp Paying Users that utilize insurance coverage to pay for services, which includes any copayments.

BetterHelp cost of revenue, exclusive of depreciation, amortization, and stock-based compensation, decreased by $3.9 million, or 6%, to $61.3 million for the three months ended March 31, 2026. The decrease was primarily driven by lower therapist costs.

BetterHelp advertising and marketing, exclusive of stock-based compensation, decreased by $16.2 million, or 12%, to $116.8 million for the three months ended March 31, 2026, primarily reflecting lower spending on digital and media advertising.

BetterHelp other segment expenses increased by $4.5 million, or 13%, to $38.5 million for the three months ended March 31, 2026. The increase was primarily driven by higher employee compensation costs and professional fees.

**Liquidity and Capital Resources**

The following table presents a summary of our cash flow activity for the three months ended March 31, 2026 and 2025 (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| **Consolidated Statements of Cash Flows - Summary** | **2026** | **2025** |
| Net cash provided by operating activities | $9516 | $15919 |
| Net cash used in investing activities | (36522) | (123268) |
| Net cash (used in) provided by financing activities | (2449) | 769 |
| Effect of foreign currency exchange rate changes | (891) | 1585 |
| Total decrease in cash and cash equivalents | $(30346) | $(104995) |

---

Our principal source of liquidity is cash generated by our operations together with our cash and cash equivalents on hand, which totaled $750.7 million as of March 31, 2026. Additionally, we entered into the five-year, $300.0 million , Revolving Credit Facility on July 17, 2025 to preserve and enhance our financial and operational flexibility. We do not, however, currently anticipate borrowing any amounts under the facility. See Note 10. "Debt" to the condensed consolidated financial statements for additional information on the Revolving Credit Facility.

We believe that our existing cash and cash equivalents will be sufficient to meet our working capital, capital expenditure, and contractual obligation needs for at least the next 12 months. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of visits, our ability to retain and/or obtain new members, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced services offerings, the continuing market acceptance of virtual care, and our debt service obligations. We may in the future enter into arrangements to acquire or invest in additional complementary businesses, services, technologies, and intellectual property rights. We may be required to seek additional equity or debt financing to fund working capital, capital expenditures and acquisitions, and to settle debt obligations. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all, which would adversely affect our business, financial condition, and results of operations.

We routinely enter into contractual obligations with third parties to provide professional services, licensing, and other products and services in support of our ongoing business. The current estimated cost of these contracts is not expected to be significant to our liquidity and capital resources based on contracts in place as of March 31, 2026.

In addition, from time to time, we may evaluate and pursue strategic transactions, including acquisitions or dispositions. The timing, size, scope, and structure of any such transactions are inherently uncertain, and we cannot predict whether any transaction will be pursued or consummated. Any strategic transaction we pursue may involve substantial cash expenditures, indebtedness, equity issuance, contingent consideration, or other financing arrangements, as well as transaction costs. Dispositions could reduce future revenues and cash flows associated with the disposed assets and may result in gains or losses on sale, impairment charges, or other accounting impacts. As a result, our future liquidity needs,

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

capital resources, and results of operations could be affected by transaction-related activities, even if a contemplated transaction is not ultimately completed.

***Cash from Operating Activities***

Cash flows provided by operating activities consisted of net loss adjusted for certain non-cash items and the cash effect of changes in assets and liabilities. Net cash provided by operating activities was $9.5 million for the three months ended March 31, 2026 compared to net cash provided by operating activities of $15.9 million for the three months ended March 31, 2025. The decrease primarily relates to the payment of annual bonuses during the first three months of the year.

The primary uses of cash from operating activities are for the payment of cash compensation, provider fees, engagement marketing, direct-to-consumer digital and media advertising, inventory, insurance, technology costs, interest expense and acquisition, integration, and transformation costs. Historically, cash compensation is at its highest level in the first quarter when discretionary employee compensation related to the previous fiscal year is paid.

***Cash from Investing Activities***

Cash used in investing activities was $36.5 million for the three months ended March 31, 2026, and $123.3 million for the three months ended March 31, 2025. Cash payments for capitalized software development costs was higher by $4.2 million during the three months ended March 31, 2026 compared to the prior year. During the three months ended March 31, 2025, we paid $64.6 million, net of cash acquired, to purchase Catapult Health and paid $27.0 million to acquire the securities of a private company.

***Cash from Financing Activities***

Cash used in financing activities for the three months ended March 31, 2026 was $2.4 million compared to cash provided by financing activities of $0.8 million for the three months ended March 31, 2025. During the three months ended March 31, 2026, $2.8 million was paid for the outstanding contingent consideration related to the acquisition of Catapult Health.

***Free Cash Flow***

The following is a reconciliation of net cash provided by operating activities to free cash flow (in thousands, unaudited):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Net cash provided by operating activities | $9516 | $15919 |
| Capital expenditures | (1660) | (2726) |
| Capitalized software development costs | (34162) | (28859) |
| Free Cash Flow | $(26306) | $(15666) |

---

Free cash flow was an outflow of $26.3 million for the three months ended March 31, 2026, compared to an outflow of $15.7 million for the three months ended March 31, 2025.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

***Interest Rate Risk and Foreign Currency Exchange Risk***

Our cash and cash equivalents are subject to interest rate volatility, which impacts the amount of interest income earned, and represents our principal market risk. A 1% change in interest rates would result in a change of interest income generated from our cash and cash equivalents by approximately $8.0 million over the next 12 months. We do not enter into investments for trading or speculative purposes.

Our convertible senior notes bear fixed interest rates so would not be exposed to changes in market interest rates. As interest rates under our Revolving Credit Facility are variable (see Note 10. "Debt" to the condensed consolidated

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

financial statements for additional information), any borrowing made under the Revolving Credit Facility would be exposed to changes in market interest rates. However, there were no amounts outstanding under the Revolving Credit Facility as of March 31, 2026, so there is currently no financial interest rate exposure.

We operate our business primarily within the U.S., which accounts for approximately 80% of our revenue. We have not historically utilized hedging strategies with respect to our foreign currency exchange exposure, however we may do so in the future.

***Concentrations of Risk and Significant Clients***

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Although we deposit our cash with multiple financial institutions in the U.S. and in foreign countries, our deposits, at times, may exceed federally insured limits or foreign equivalent. Our cash equivalents are primarily invested in institutional money market funds.

No single Client represented over 10% of consolidated revenues for each of the three months ended March 31, 2026 or 2025. For the Integrated Care segment, a significant portion of our revenue is derived from large enterprises, mainly health plans. Revenue from the five largest Clients accounted for 31% of total Integrated Care segment revenue for each of the three months ended March 31, 2026 and 2025. For further information, see "Risk Factors—Risks Related to Our Business and Industry—We operate in a competitive industry, and if we are not able to compete effectively, our business, financial condition, and results of operations will be harmed," and "—A significant portion of our revenue comes from a limited number of Clients, the loss of which could have a material adverse effect on our business, financial condition and results of operations" included in our 2025 Form 10-K.

For the BetterHelp segment, there is no significant concentration risk as substantially all revenue is generated from individuals in the direct-to-consumer market.

**Item 4. Controls and Procedures**

***Management's Report on Internal Control over Financial Reporting***

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Principal Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")). Based on that evaluation, our Chief Executive Officer and Principal Financial Officer concluded that as of March 31, 2026, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

***Changes in Internal Control Over Financial Reporting***

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are subject to legal proceedings, claims and litigation arising in the ordinary course of our business. Descriptions of certain legal proceedings to which we are a party are contained in Note 14. "Commitments and Contingencies," to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q and are incorporated by reference herein.

**Item 1A. Risk Factors**

For a discussion of potential risks and uncertainties related to our Company see the information in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the "Special Note Regarding Forward-Looking Statements" section in Part I, Item 2, of this Quarterly Report on Form 10-Q.

**Item 5. Other Information**

During the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

**Item 6. Exhibits**

**Exhibit**

**Index**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
|<br>**Exhibit<br>Number** |<br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing<br>Date** | **Filed<br>Herewith** |
| 3.1 | <u>[Seventh Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm)</u> | 8-K | 001-37477 | 3.1 | 6/2/22 |  |
| 3.2 | <u>[Seventh Amended and Restated Bylaws of Teladoc Health, Inc.](https://www.sec.gov/Archives/edgar/data/1477449/000147744924000023/tdoc-20231231xexx32.htm)</u> | 10-K | 001-37477 | 3.2 | 2/23/24 |  |
| 31.1 | <u>[Chief Executive Officer](tdoc-20260331xexx311.htm)[and](tdoc-20260331xexx311.htm)[Principal Financial Officer](tdoc-20260331xexx311.htm)[—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tdoc-20260331xexx311.htm)</u> |  |  |  |  | \* |
| 32.1 | <u>[Chief Executive Officer](tdoc-20260331xexx321.htm)[and Principal Financial Officer](tdoc-20260331xexx321.htm)[—Certification pursuant to Rule13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tdoc-20260331xexx321.htm)</u> |  |  |  |  | \*\* |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the<br>Inline XBRL document. |  |  |  |  | \* |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |  |  |  |  | \* |
| 101.CAL | XBRL Taxonomy Calculation Linkbase Document. |  |  |  |  | \* |
| 101.DEF | XBRL Definition Linkbase Document. |  |  |  |  | \* |
| 101.LAB | XBRL Taxonomy Label Linkbase Document. |  |  |  |  | \* |
| 101.PRE | XBRL Taxonomy Presentation Linkbase Document. |  |  |  |  | \* |
| 104 | Cover Page Interactive Data File – The Cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |  |  |  |  |  |

---

___________________________

\*Filed herewith.

\*\*Furnished herewith.

------

<u>[**Table of Contents**](#i4494206693f04f999e24db88e0075fbb_7)</u>

<u>Signatures</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **TELADOC HEALTH, INC.** | **TELADOC HEALTH, INC.** |
| Date: April 30, 2026 | By: | /s/ CHARLES DIVITA, III |
|  | Name: | Charles Divita, III |
|  | Title: | Chief Executive Officer <br>and Principal Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**Certification**

I, Charles Divita, III, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Teladoc Health, Inc. (the "registrant") for the period ended March 31, 2026;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: April 30, 2026 |
| /s/ CHARLES DIVITA, III |
| Charles Divita, III |
| *Chief Executive Officer and Principal Financial Officer* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Teladoc Health, Inc. (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Charles Divita, III, Chief Executive Officer and Principal Financial Officer of the Company, certify, to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| Date: April 30, 2026 |
| /s/ CHARLES DIVITA, III |
| Charles Divita, III |
| *Chief Executive Officer and Principal Financial Officer* |

---

<br>